Britannica
Sources used in this answer
- pharmaceutical industry
- Eli Lilly and Company - 1940s–1960s: World War II and postwar expansion
- pharmaceutical industry - Public influence on drug regulation
- history of medicine - Penicillin
- pharmaceutical industry - Regulation by government agencies
- history of medicine - Other antibiotics
- pharmaceutical industry - Pharmaceutical industry in the modern era
- pharmaceutical industry - Transitions in drug discovery
How did the pharmaceutical industry change after World War II?
Created from Britannica articles
using AI.
AI can make mistakes, so verify using Britannica articles.
pharmaceutical industry
A technician withdrawing deep-frozen cells for in vitro culture at a laboratory of a German pharmaceutical company.
Following World War II, the pharmaceutical industry underwent significant expansion and transformation, driven by wartime production demands and subsequent scientific advancements.
- Mass Production and Scaling: During the war, companies like Eli Lilly scaled up manufacturing for critical supplies such as penicillin and blood plasma. Post-war, this infrastructure was repurposed for broader commercial production, facilitating the rapid development of new antibiotics and other medications.1
- Global Growth: The industry shifted toward becoming a complex, multinational enterprise, with major companies expanding their research, manufacturing, and sales operations across Africa, Asia, and South America.12
- Regulatory Evolution: The post-war era saw a strengthening of government oversight. Following drug-related catastrophes like the thalidomide crisis in the 1960s, public demand led to more restrictive legislation to ensure drug safety. Conversely, the industry also saw the development of expedited approval processes for life-threatening conditions, reflecting a constant flux between safety and the need for innovation.34
- Research Symbiosis: A critical shift occurred in the relationship between public institutions and private firms, with governments increasingly supporting fundamental research that companies utilized to develop new pharmaceutical products.5